美國Vertex www.vrtx.com 
Vertex公司是一家專注于研究口服小分子藥劑新的開發(fā)方法、使用基于結(jié)構(gòu)的合理藥劑進行設(shè)計的先驅(qū)性的醫(yī)藥品研究開發(fā)企業(yè)，主要設(shè)計開發(fā)防止HIV感染、AIDS自免疫系統(tǒng)缺失、癌癥、血紅蛋白障礙、炎癥等新藥。近年來這家公司的一些新藥頻受關(guān)注，比如今年，其囊性纖維化治療藥物VX- 770的臨床三期研究被分析師認(rèn)為取得了歷史性的突破：這種藥物起效明顯，在一秒鐘內(nèi)就能引發(fā)肺功能改善——即FEV1用力呼氣量——在48周與安慰劑的對比試驗中，所有關(guān)鍵的次要終點在參與VX- 770試驗組的成員都得到改進。除此之外，其最新的治療丙型肝炎的藥物(telaprevir)也通過FDA的審批。
 
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.
Vertex isn’t a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Vertex has ongoing worldwide research programs and sites in the U.S., U.K. and Canada and employs over 1800 people.